Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer

• DOI: 10.1016/j.ejso.2022.04.018
• Publication Date: 2022-04-27T15:47:56Z
• Authors: Ting-Ying Lee; Chih-Hsiung Hsu; Hsiu-Lung Fan; Guo-Shiou Liao; Teng-Wei Chen; De-Chuan Chan
• Keywords: Hyperthermic Intraperitoneal Chemotherapy; Lymphadenectomy

Patients with clinical T4 gastric cancers have high recurrence rates and low 5-year overall survival (OS) despite radical gastrectomy D2 lymphadenectomy adjuvant chemotherapy. The invisible peritoneal metastasis may result in local due to the tumor invading serosa nearby organs. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) has been suggested as an treatment strategy these patients. We evaluated efficacy of prophylactic HIPEC post-gastrectomy for patients cancer.We retrospectively reviewed data from 132 cancer who underwent + between 2014 2020. Thirty-five also perioperatively. used propensity score matching (PSM) reduce selection bias. risk factors compared OS disease-free (DFS) groups.A total eligible were included study. Seventy preoperative patient characteristics homogeneous post-PSM. seemed postoperative but did not influence distant metastasis. advanced N stage, ascites, lymphovascular invasion. (adjusted hazard ratio, 0.37; 95% CI, 0.17 0.81; p = 0.035) DFS 0.33; 0.15 0.72; 0.017) better group than alone group.Prophylactic plus can improve cancer.